Enzymatica Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Enzymatica hat ein Gesamteigenkapital von SEK83.9M und eine Gesamtverschuldung von SEK28.0M, was einen Verschuldungsgrad von 33.4% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK137.1M bzw. SEK53.1M.

Wichtige Informationen

33.4%

Verhältnis von Schulden zu Eigenkapital

SEK 28.01m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 26.92m
Eigenkapital	SEK 83.93m
Gesamtverbindlichkeiten	SEK 53.14m
Gesamtvermögen	SEK 137.07m

Jüngste Berichte zur Finanzlage

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Jul 22

Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Feb 18

Recent updates

Insider Buying: The Enzymatica AB (STO:ENZY) Director Just Bought kr102k Worth Of Shares

Mar 16

Enzymatica AB (STO:ENZY) Is About To Turn The Corner

Mar 07

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ENZYDie kurzfristigen Aktiva des Unternehmens (SEK50.2M) übersteigen seine kurzfristigen Passiva (SEK27.8M).

Langfristige Verbindlichkeiten: ENZYDie kurzfristigen Vermögenswerte des Unternehmens (SEK50.2M) übersteigen seine langfristigen Verbindlichkeiten (SEK25.3M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ENZYDie Nettoverschuldung im Verhältnis zum Eigenkapital (1.3%) wird als zufriedenstellend angesehen.

Schulden abbauen: ENZYDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 4.3% auf 33.4% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ENZY hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: ENZY hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 15.1% pro Jahr abnimmt

Enzymatica Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Recent updates

Independent Director recently bought kr4.6m worth of stock

Consensus EPS estimates fall by 21%, revenue upgraded

Enzymatica AB (Publ) Announces Interim Results from Independent Clinical Study of Coldzyme® Show Duration of Illness Lowered by Approximately 5 Days

Consensus revenue estimates fall by 16%

Forecast to breakeven in 2026

New major risk - Financial position

First quarter 2024 earnings released: kr0.11 loss per share (vs kr0.091 loss in 1Q 2023)

New minor risk - Shareholder dilution

Independent Director recently sold kr60k worth of stock

Enzymatica AB (publ) Announces Composition of Nomination Committee

New minor risk - Profitability

No longer forecast to breakeven

Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 27.37614 million.

Independent Director recently sold kr900k worth of stock

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.30 loss per share (vs kr0.45 loss in FY 2022)

Enzymatica AB (publ) to Report Fiscal Year 2023 Final Results on Apr 09, 2024

New major risk - Financial position

Enzymatica AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Consensus revenue estimates decrease by 30%

Third quarter 2023 earnings released: kr0.056 loss per share (vs kr0.085 loss in 3Q 2022)

Independent Chairman recently bought kr564k worth of stock

Enzymatica AB (publ) Announces Interim Report from Clinical Study: ColdZyme Significantly Reduces Rhinovirus Viral Load and Symptoms of Sore Throat

Enzymatica AB (publ) Announces New Study

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Second quarter 2023 earnings released: kr0.07 loss per share (vs kr0.10 loss in 2Q 2022)

Independent Director recently bought kr157k worth of stock

Independent Director recently bought kr157k worth of stock

Independent Chairman recently bought kr414k worth of stock

First quarter 2023 earnings released: kr0.091 loss per share (vs kr0.12 loss in 1Q 2022)

Independent Director recently sold kr1.5m worth of stock

Forecast to breakeven in 2025

Consensus revenue estimates decrease by 15%

Full year 2022 earnings released: kr0.45 loss per share (vs kr0.31 loss in FY 2021)

Enzymatica AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Enzymatica AB (publ) to Report Nine Months, 2023 Results on Nov 07, 2023

No longer forecast to breakeven

Third quarter 2022 earnings released

Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 74.6622 million.

Consensus forecasts updated

Second quarter 2022 earnings released

Enzymatica AB (publ) Announces New Data from an Ongoing In-Vitro Study

Forecast breakeven date moved forward to 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Enzymatica AB's Mouth Spray to Be Launches in Turkey

Chairman recently bought kr1.7m worth of stock

Enzymatica and Sanofi Launches Mouth Spray in Mexico

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Enzymatica AB to Report Fiscal Year 2021 Final Results on Mar 31, 2022

Independent Director recently sold kr4.0m worth of stock

Now 24% undervalued after recent price drop

Estimating The Fair Value Of Enzymatica AB (STO:ENZY)

Forecast breakeven date pushed back to 2023

Chairman recently bought kr1.5m worth of stock

Director recently bought kr4.7m worth of stock

Consensus revenue estimates fall to kr82.0m

Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company

Head of Corporate Communications Carl-Johan Wachtmeister has left the company